September 2025
1. MA Z, He W, Zhang Y, Mao X, et al
   First mammography screening participation and breast cancer incidence and mortality in the subsequent 25 years: population based cohort study.
   BMJ. 2025;390:e085029.
   

   >> Share

   
   
2. XIA Y, Zhu Y, Ling L, Xu F, et al
   Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial.
   BMJ. 2025;390:e084290.
   

   >> Share

   
   August 2025
3. SANCHEZ MJ, Petrova D
   Second primary cancers in breast cancer survivors.
   BMJ. 2025;390:r1798.
   

   >> Share

   
   
4. BOWIE K
   Risk of second cancer after early breast cancer is low, study finds.
   BMJ. 2025;390:r1819.
   

   >> Share

   
   
5. MACKENZIE M, Stobart H, Dodwell D, Taylor C, et al
   Patients need information on the risk of second cancer after early breast cancer.
   BMJ. 2025;390:r1584.
   

   >> Share

   
   
6. MCGALE P, Dodwell D, Challenger A, Cutter D, et al
   Second cancers in 475 000 women with early invasive breast cancer diagnosed in England during 1993-2016: population based observational cohort study.
   BMJ. 2025;390:e083975.
   

   >> Share

   
   July 2025
7. RYSER MD, Thomas SM, Li Y, Lynch T, et al
   Cancer outcomes in women without upfront surgery for ductal carcinoma in situ: observational cohort study.
   BMJ. 2025;390:e083542.
   

   >> Share

   
   April 2025
8. O'DOWD A
   NICE recommends "targeted" drug capivasertib for advanced breast cancer.
   BMJ. 2025;389:r762.
   

   >> Share

   
   December 2024
9. PARK B, Chang Y, Ryu S, Tran TXM, et al
   Trajectories of breast density change over time and subsequent breast cancer risk: longitudinal study.
   BMJ. 2024;387:e079575.
   

   >> Share

   
   
10. ROBINSON A
    Advances in breast cancer and bowel cancer treatments ... and other research.
    BMJ. 2024;387:q2699.
    

    >> Share

    
    October 2024
11. HE M, Jiang YZ, Gong Y, Fan L, et al
    Intensive chemotherapy versus standard chemotherapy among patients with high risk, operable, triple negative breast cancer based on integrated mRNA-lncRNA signature (BCTOP-T-A01): randomised, multicentre, phase 3 trial.
    BMJ. 2024;387:e079603.
    

    >> Share

    
    
12. MASON S
    Risk prediction in early triple negative breast cancer.
    BMJ. 2024;387:q2088.
    

    >> Share

    
    
13. TANNE JH
    Breast cancer: Cases rising among younger US women although deaths are dropping.
    BMJ. 2024;387:q2199.
    

    >> Share

    
    September 2024
14. TANNE JH
    US women must be told breast density after mammogram, says FDA.
    BMJ. 2024;386:q2045.
    

    >> Share

    
    
15. LEE SF, Kennedy SKF, Caini S, Wong HCY, et al
    Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis.
    BMJ. 2024;386:e079089.
    

    >> Share

    
    August 2024
16. BAUM M
    Breast cancer screening does not improve length or quality of life.
    BMJ. 2024;386:q1752.
    

    >> Share

    
    
17. AUTIER P
    Breast cancer screening expansion: modelling doesn't reflect real life and should not be used to update guidance.
    BMJ. 2024;386:q1750.
    

    >> Share

    
    July 2024
18. RIMMER A
    Navigating breastfeeding through cancer treatment.
    BMJ. 2024;386:q1284.
    

    >> Share

    
    June 2024
19. BELL KJ, Nickel B, Pathirana T, Blennerhassett M, et al
    Breast cancer screening from age 40 in the US.
    BMJ. 2024;385:q1353.
    

    >> Share

    
    May 2024
20. TANNE JH
    US expert panel says breast cancer screening should begin at 40.
    BMJ. 2024;385:q1020.
    

    >> Share

    
    April 2024
21. WISE J
    Breast cancer: Inaction on inequalities has led to unequal progress, say experts.
    BMJ. 2024;385:q854.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share